As such, biopharmaceutical companies and researchers around the world are working to identify new, effective and safe treatments to help this growing patient population. As a consequence patient reported outcomes (PRO) measures are increasingly being used to measure health status, quality of life, and the economic burden.
One such instrument is the DHP-18, which as a measure of the psychological and behavioural impact of living with diabetes was initially developed as a patient self-completion instrument for use across a range of settings including clinical trials, population and community surveys and research studies. The DHP was recently adopted by the Department of Health into the next generation PROMs program for the NHS.
CRF Health in association with DHP Research and Isis Outcomes presented as part of the eCOA Webinar Series – Patient Reported Outcome Measures in Diabetes Clinical Trials – in which the following topics were discussed:
- The psychological impact on adherence and control
- PROs in real world data collection
- Disease-specific versus generic — making the choice
- The Diabetes Health Profile (DHP) and what it measures
To download the webinar go to: http://bit.ly/16Uik1B